Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,226,743 papers from all fields of science
Search
Sign In
Create Free Account
crizotinib
Known as:
(R)-Crizotinib
, 2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-
, (R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine
Expand
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
11 relations
ALK protein, human
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Receptor Tyrosine Kinase Inhibitors [MoA]
Expand
Narrower (2)
PF-2341066
Xalkori
Broader (3)
Protein Kinase Inhibitors
Pyrazoles
Pyridines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Brigatinib Outperforms Crizotinib as First-Line Therapy.
Cancer Discovery
2019
Corpus ID: 209489776
The latest results from the phase III ALTA-1L trial suggest that the ALK inhibitor brigatinib is superior to crizotinib in…
Expand
Review
2018
Review
2018
Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
L. Claxton
,
Joanne O’Connor
,
N. Woolacott
,
Kath Wright
,
R. Hodgson
PharmacoEconomics (Auckland)
2018
Corpus ID: 52936643
The National Institute for Health and Care Excellence (NICE) invited the company that manufactures ceritinib (Zykadia®, Novartis…
Expand
2016
2016
Determination of crizotinib in human plasma by HPLC-MS/MS
Guo-Fang Bi
,
Guang-tao Hao
,
+6 authors
Heng-Yan Qu
2016
Corpus ID: 98913850
Objective To determine the crizotinib in human plasma by established HPLC- MS/MS method. Methods The plasma was treated with…
Expand
2016
2016
Comparative Efficacy of Ceritinib and Crizotinib as Initial Anaplastic Lymphoma Kinase-targeted Therapies in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: an Adjusted…
D. Tan
,
A. Araújo
,
+4 authors
Geoffrey Liu
2016
Corpus ID: 78742334
Abstract Crizotinib and ceritinib have been developed to treat advanced or metastatic non-small cell lung cancer (NSCLC) by…
Expand
2015
2015
A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers.
Gregory Riely
,
H. Yu
,
+7 authors
M. Ginsberg
2015
Corpus ID: 78848166
8064 Background: Patients with ALK + non-small cell lung cancer (NSCLC) initially respond to crizotinib, but eventually develop…
Expand
2015
2015
Successful Oral Desensitization in a Patient With Hypersensitivity Reaction to Crizotinib.
J. Sánchez‐López
,
N. Viñolas
,
+4 authors
Antonio Valero
Journal of investigational allergology & clinical…
2015
Corpus ID: 42069664
2014
2014
Circulating tumour cells go green
R. Hoffman
Gut
2014
Corpus ID: 206960743
Circulating tumour cells (CTCs) are being used for the prediction of disease progression and drug sensitivity for various types…
Expand
2014
2014
Abstract 957: The ALK inhibitor LDK378 overcomes crizotinib resistance in non-small cell lung cancer
L. Friboulet
,
Nanxin Li
,
+21 authors
J. Engelman
2014
Corpus ID: 70469541
Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements are sensitive to the ALK…
Expand
2013
2013
Inimitable Imatinib: the range of targeted tumours expands to include T-cell lymphoma
Suzanne D. Turner
Leukemia
2013
Corpus ID: 27385155
Anaplastic large cell lymphoma, anaplastic lymphoma kinase + (ALCL, ALK+), has a relatively good prognosis but also a high rate…
Expand
2011
2011
Abstract A232: In vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori.
E. Ardini
,
M. Menichincheri
,
+10 authors
A. Galvani
2011
Corpus ID: 84570283
The Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase with a recognized role in the pathogenesis of different tumors…
Expand